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Safe, eﬃcient, and speciﬁc delivery of therapeutic genes remains an important bottleneck for the development of gene therapy.
Synthetic, nonviral systems have a unique pharmaceutical proﬁle with potential advantages for certain applications. Targeting of the
syntheticvectorimprovesthespeciﬁcityofgenemedicinesthroughamodulationofthecarriers’biodistribution,thuscreatingadose
diﬀerential between healthy tissue and the target site. The biodistribution of current carrier systems is being inﬂuenced to a large
extentbyintrinsicphysicochemicalcharacteristics,suchaschargeandsize.Consequently,suchnonspeciﬁcinteractionscaninterfere
with speciﬁc targeting, for example, by ligands. Therefore, a carrier complex should ideally be inert, that is, free from intrinsic
properties that would bias its distribution away from the target site. Strategies such as coating of DNA carrier complexes with
hydrophilicpolymershavebeenusedtomasksomeoftheseintrinsictargetingeﬀectsandavoidnonspeciﬁcinteractions.Preexisting
endogenousligand-receptorinteractionshavefrequentlybeenusedfortargetingtocertaincelltypesortumours.Recentlyexogenous
ligandshavebeenderivedfrommicroorganismsor,likeantibodiesorphage-derivedpeptides,developeddenovo.Inanimalmodels,
such synthetic vectors have targeted remote sites such as a tumour. Furthermore, the therapeutic proof of the concept has been
demonstrated for ﬁtting combinations of synthetic vectors and therapeutic gene.
INTRODUCTION
The eﬃcient and speciﬁc delivery of therapeutic genes
to a target site is a challenge that will need to be over-
come in order to tap into the promise and potential of
gene medicines [1]. Over the last decade a number of
promising synthetic, nonviral systems gene delivery sys-
tems have been developed and a proﬁle of their poten-
tial advantages and disadvantages has emerged. Synthetic
vectors have advantages relating to pharmaceutical issues,
safety, and ease of use but tend to be less eﬃcient than
some viral systems [2, 3].
One of the critical issues that determine eﬃcacy and
safety of a therapeutic approach is its speciﬁcity, which
is based on the recognition and exploitation of diﬀer-
entials between the diseased site and healthy tissue. As
these diﬀerentials exist on diﬀerent levels—molecular to
systemic—it is crucial that each element of a potential
gene medicine is selected with a view to exploit poten-
tial diﬀerences. The basic modules of a gene medicine,
namelycarrier,gene,andeﬀectorprotein,eachcontribute
to the overall activity and speciﬁcity proﬁle. Further levels
of speciﬁcity may be added through the use of, for exam-
ple, prodrugs, which the eﬀector protein then acts upon.
Targeting provides a generic strategy to improve the
speciﬁcityofapharmaceuticalformulationindependently
of the speciﬁcity of the drug or gene itself, primarily
by creation of a dose diﬀerential between healthy and
diseased tissue. This review will examine strategies and
speciﬁc challenges relating to the targeting of synthetic
gene vector systems.
SYNTHETIC GENE DELIVERY VECTORS
Viral and nonviral synthetic, nonviral systems gene
delivery vectors are characterised by a proﬁle of poten-
tial pharmaceutical advantages and disadvantages, which
need to be matched to the therapeutic strategy [3]. While
short-term expression of the gene, for example, with a
synthetic vector, may be acceptable for immunisation, an
integrating viral vector may provide a more sustained ex-
pression suitable for gene replacement therapy.
Important advantages of synthetic vector systems are
their safety, lack of immunogenicity, very low frequency
of integration, and relative ease of large-scale produc-
tion, which makes them more akin to conventional phar-
maceutical excipients. These systems are also very ﬂex-
ible with regards to the therapeutic nature of size of
the gene, as even mammalian artiﬁcial chromosomes of
60mega bases have been transfected successfully [4].
The potential disadvantage of lower eﬃciency pre-
sents the ﬂip side of the coin. However, one needs to
bear in mind that therapeutic eﬃcacy will ultimately de-
pend on the suitable combination of vector and gene.
For a number of synthetic systems therapeutic potential
has been demonstrated, for example, in tumour models
in vivo [5]. The systems also allow repeat dosing which
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gene expression can be increased signiﬁcantly by geneti-
cally optimising of the expression plasmid [7].
Packaging
One of the key concepts for the use of drug carriers
in general is “packaging”: delivery systems fulﬁl a num-
berofgenericfunctionsanalogoustoamailpackage,such
as, for example, protection of content, ease of handling,
and an address for delivery. The pharmaceutical proper-
ties of the package/delivery system are determined by the
box/carrier and are largely independent from the content,
which only becomes relevant once the package has been
delivered.
In the case of the synthetic vector systems, the active
principle (pharmacophore) is the plasmid DNA. While
(naked) plasmid DNA could be regarded as a macro-
molecular drug, its vulnerability to enzymatic degrada-
tion (nucleases) in biological ﬂuids (t1/2 plasma = 1.2min
[8])makesaprotectivepackagingmandatoryformostap-
plications.
“Packaging” systems based on synthetic, nonviral vec-
tors fall into two main groups, water-soluble polymers
and cationic lipids/vesicles. (Another group of synthetic
c a r r i e rm a t e r i a l si sb a s e do nt h eu s eo fp e p t i d e s[ 9]w h i c h
usually contain a group of charged amino acids (eg, ly-
sine) to complex DNA.)
Complexformationandphysicochemistry
The principles that govern the formation of the diﬀer-
ent complexes are similar, but some physicochemical dif-
ferences exist, which aﬀect some of the system’s biological
properties.
The complex formation between plasmid DNA and
the carrier is initially electrostatic, that is, induced by the
attraction between the anionic DNA and the cationic car-
rier material. This attraction leads to the formation of a
DNA-carrier aggregate, so called polyplex, in the case of
polymers, or lipoplexes for cationic lipids, respectively.
The stability of these complexes depends on the
strengthoftheelectrostaticinteractionandthusontheto-
tal charge and the charge density of the carrier molecule.
Complex formation is not always easily controlled, as the
process is inﬂuenced by stoichiometric as well as kinetic
factors [10]. The resulting complexes are particles with a
size ranging from less than 100nm to over 1µm.
The total charge of the carrier molecule also depends
on the number of attachment points per molecule: in
the case of a polymer binding to DNA it is a many-
to-many relationship, that is, each molecule provides
multiple interaction opportunities; the cationic lipids on
the other hand will normally be monovalent leading to
a many-to-one relationship. Therefore, the noncovalent
self-assembly processes are central to stabilising these
types of systems. For amphiphilic carrier material such as
cationic lipids, an additional stabilising factor is based on
the phase separation, which leads to the sandwiching of
the DNA between lipid layers.
In general, the size of the complex will be greater than
that of the starting material, for example, vesicles, and
may in fact continue to increase in size and ultimately
lead to precipitation if the formulation is not colloidally
stable.
In general, colloidal stability is being achieved by
working with an excess of cationic charge, that is, carrier
material, to ensure complete coating of the DNA to create
charged complexes that are stabilised by the electrostatic
repulsion between the particles. The majority of synthetic
gene delivery systems carry a positive charge and are thus
prone to interact with negatively charged molecules and
surfaces. (While DNA “packaging” in the overwhelm-
ing majority of systems is based on charge-charge in-
teractions, a few systems (eg, for DNA vaccination) aim
to encapsulate DNA in the aqueous core of a vesicle
[11, 12].)
This nonspeciﬁc interaction of positively charged
complexes with cell surface molecules such as gly-
cosaminoglycans is in fact an important factor in deter-
mining overall uptake and downstream transfection ef-
ﬁciency [13, 14, 15]. While this nonspeciﬁc binding and
uptake eﬀect may be useful for in vitro transfection and
locoregional applications, it also introduces the potential,
for a number of interactions in vivo that will bias the
biodistribution and may compromise the stability of the
delivery systems [2].
The adsorption of serum proteins can induce a num-
berofeﬀectssuchascomplexdestabilisation,aggregation,
or retargeting. The binding of cellular elements such as
erythrocytes [16] and platelets [17] can lead to extensive
aggregation and potentially acute toxicity.
TARGETING
In the context of drug and gene delivery systems, we
deﬁne “targeting” as any strategy that increases speciﬁcity
primarily through a modulation of the carriers’ biodistri-
bution.
Given the complexity of the biological barriers that
need to be overcome for the targeting to a remote site,
locoregional administration represents a very pragmatic
alternative to the targeting after systemic administration.
Locoregionaladministration
The feasibility of locoregional administration as an
approach to improve speciﬁcity depends very much on
the disease and the therapeutic strategy. For situations
where one aims to treat a small number of easily acces-
sible disease sites, it will in fact often be the method of
choice. Furthermore, it is not necessarily required for the
gene complex itself to reach the diseased site: local pro-
duction of a remotely acting eﬀector protein may be more
eﬃcient (eg, local production of growth factors which act
on a tumour or APC stimulation for immunotherapy).
In a mouse model of intrahepatic hepatocellular car-
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evident; transgene expression and toxicity were clearly su-
perior after intratumour application of the gene medicine
compared to either administration into the tail vein or the
portal vein [18].
Anatomical barriers, such as the blood-brain-barrier,
are another reason for the use of locoregional adminis-
tration, which separate the organ from the systemic cir-
culation. The blood-brain barrier seals the brain oﬀ from
the systemic circulation and local administration of gene
medicines is a practical way of circumventing this barrier.
The intrathecal administration of a lipoplex with anti-
apoptotic transgenes into the cerebrospinal ﬂuid allevi-
ated postischemic damage in a model of ischemic brain
damage [19].
One of the most important parenteral administration
routes is through the oral/nasal mucosa and the lung. Lo-
cal delivery using the lung is the ﬁrst choice for the ther-
apy of cystic ﬁbrosis, that is, typically aiming to replace
the faulty CFTR gene to restore the faulty transport of salt
in the lung epithelium. Clinical trials forcystic ﬁbrosis us-
ing lipoplexes were among the ﬁrst to establish the safety
of these vectors [20] and the eﬃcacy of repeat dosing [6]
in a clinical setting.
Althoughlocoregionaladministrationoﬀersmanyad-
vantageous route-speciﬁc barriers, for example, sputum
[21] may need to be taken into consideration and carriers
optimised accordingly [22].
Targetingaftersystemicadministration
Targeting in drug and gene delivery usually has a nar-
rower context than suggested in the above deﬁnition and
refers to approaches, which aim to achieve a diﬀerential
in drug concentration between a remote target site and
the body in general.
When trying to target drugs or DNA complexes to a
remote site in the body, the simplest starting point is an
intravenous injection; any other means of administration
(eg, intramuscular or subcutaneous injection) leads to a
greatercomplexityofthesystemasadditionalbarrierswill
have to be overcome to gain access to the systemic circu-
lation.
Conventionally, targeting strategies have been cat-
egorized as either “active” or “passive.” We suggest a
more useful way of thinking about targeting of delivery
systems may be to distinguish between targeting prop-
erties intrinsic to the carrier system, which are largely
based on the systems’ physicochemistry, and indepen-
dent, extrinsic targeting functions, for example, ligands
(cf. Figure 1).
To allow speciﬁc ligand-directed distribution to a tar-
get site, a carrier/complex should ideally be inert, that is,
free from inherent properties that would bias the biodis-
tribution. (Coming back to the picture of the “package,”
one could say that the site of delivery should be deter-
mined only by the address label and that the nature of
the box should not inﬂuence the way the parcel is being
processed.)
INTRINSIC TARGETING
Because of the complexity of biological systems and
the plethora of potential interactions, it could be argued
that there is no such thing as an untargeted delivery sys-
tem: for any set of intrinsic physicochemical carrier prop-
erties there are speciﬁc biological interactions and eﬀects
that will bias its biodistribution. In order to be able to
speciﬁcally target synthetic gene delivery systems, it is
therefore important to understand the bias of biodistri-
bution inherent to the systems’ physicochemistry. In the
context of a suitable therapeutic strategy, the intrinsic
properties of selected systems can actually facilitate an ac-
cumulation at a remote target site.
Charge
While the cationic charge of DNA complexes compli-
cates the systemic administration of such gene medicines,
it is clear that this interaction produces a distinctive pat-
ternofbiodistribution[17]whichma ypotentiallybeused
with an advantage to target sites of increased vascular
growth such as tumours. Some cationic vesicles have been
shown to have a 15–33-fold higher uptake in angiogenic
endothelial cells of the tumour neovasculature than in
corresponding normal endothelial cells [23].
After intravenous administration of DNA complexes,
expression in the lung tends to be one to two orders of
magnitude higher than in other organs. The mechanisms
behind the lung targeting eﬀect are not entirely clear [24]
but have frequently been linked to carrier charge [25].
There is also evidence that the nature of the carrier mate-
rialsplaysarole:lungendothelialcellsshowsignsofactive
transport of PEI complexes [26] with a potential involve-
ment of an endogenous polyamine transporter [27].
Whilechargeisanintrinsicpropertyofmostsynthetic
vectors, it may also be utilised as an extrinsic targeting
function, for example, for the retargeting of adenovirus
to the lung [28].
Size
Complex size is a potentially important property of
synthetic gene delivery vectors. DNA complexes tend to
formparticulatesystems(ie,sizerangeof0.05–1µm)with
the exact size depending on a number of factors such as,
for example, DNA to carrier ratio, total concentrations,
ionic strength of the buﬀer, and kinetics of mixing. The
lowerlimitoftheparticles’sizeisnoteasilyadjustableand
is thus intrinsic to any given formulation.
For many gene therapy applications, the target cells
will form a part of the parenchyma or interstitium of the
organ and the access to these cells is restricted for partic-
ulate drug carriers after vascular administration. This is
because macromolecules and particulate carriers can only
extravasate from the vasculature at specialised sites, for
example, the liver or spleen, where the endothelial lining
hassuitablegaps,socalledfenestrae,whichallowparticles
of around 200nm or smaller to pass [29].152 Andreas G. Sch¨ atzlein 2003:2 (2003)
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Figure 1. Targeting of synthetic vector systems. Schematic summary of factors important for the speciﬁc targeting of synthetic gene
delivery systems. The mechanism of DNA packaging by cationic vectors, for example, vesicle, leads to the formation of condensed
particles, which carry a positive charge. Particle size and charge are intrinsic physicochemical properties of these DNA complexes that,
ininteractionwiththebody,resultinamodiﬁedbiodistribution(eg,lungortumouraccumulation).Inordertoallowtheuseofmore
speciﬁc ligands, intrinsic targeting functions need to be masked, for example, by coating with hydrophilic polymers. These more inert
carriers can then be directed speciﬁcally to a remote target site through the use of endogenous or exogenous ligands to allow targeting
of diﬀerentials between target site and healthy tissue on various levels.
Thus, size can become a potentially important intrin-
sic property of synthetic gene delivery systems that will
limitorganaccessandmodulatebiodistributionatthecel-
lular level [17, 30, 31, 32].
While many studies compare the relative transfection
eﬃciencies of formulations using “bulk reporter assays”
(eg, based on organ lysates using luminescence), there is
less information available about the histological distribu-
tion of the complexes and transgene expression within an
organ [33]. In fact, most assays do not provide a straight-
forward link between quantitation and distribution of
transgene expression.
The lung and liver tend to be the main organs of
biodistribution after systemic administration and paren-
chymal expression has been reported in both of these or-
gans. In the case of the liver, the fenestrations may play an
important role in allowing gene medicines access to the
parenchyma and increased hydrostatic pressure has been
used to widen those gaps and thus improve delivery [34].
For the lung, it is not clear what factorsare involved in
overcomingtheendothelialbarriersbutanactivetranscel-
lular transport has been observed for polyethylenimine
(PEI) polyplexes in the lung [26].
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size however, can also potentially be used for targeting:
solid tumours growing over a size of a few millimetres
recruit additional blood supply in the process of neovas-
cularisation [35] which produces rapidly sprouting ves-
sels with a “leaky” endothelial lining [36, 37]. Drug carri-
ers can extravasate this “leaky” tumour vasculature and
accumulate in perivascular clusters within the tumour.
This “enhanced penetration and retention” (EPR) eﬀect
[38] allows the targeting of long circulating macromolec-
ular or particulate drug carriers to tumours [39, 40, 41]
and could potentially also be used with suitable synthetic
gene delivery systems.
Both, charge and size of the carrier thus represent im-
portant intrinsic properties of a formulation but many
other aspects of physicochemistry will potentially also in-
ﬂuence the biodistribution. This intrinsic bias will of-
ten interfere with more speciﬁc targeting eﬀorts. How-
ever, the example of the EPR eﬀect-based targeting to
tumours demonstrates that these eﬀects could poten-
tially also be used for the targeting of a suitable gene
medicine.
Targeting based on the physicochemical properties of
the package is not necessarily based only on the intrinsic
properties: the addition of cationic charges to uncharged
virus particles demonstrates the utility of charge as an ex-
trinsic factor for the retargeting of adenovirus to the lung
[28].
Minimizingbiodistributionbias
Strategies to minimise bias from these intrinsic eﬀects
have been predominately focused on charge shielding and
steric stabilisation.
In drug targeting, the method of using water-soluble
PEG chains which create a steric barrier around the drug
carrier is well established [42] and has since been applied
to various gene delivery systems. PEG-phospholipid con-
jugates have been used to stabilise lipoplexes [43]a n d
polyplexes. Polyplex stabilisation with PEG was achieved
through the use of polylysine block [44]o rc o m bt y p e
copolymers[45,46],alsoafteradsorption[47]orcovalent
coupling [16] to PEI polyplexes, and by covalent coupling
to chitosan nanoparticles [48].
Other water-soluble materials that have helped to re-
duce the eﬀects of charge-based interactions are HPMA,
which has been used in conjunction with polylysine [49]
or PEI polyplexes [50] and block copolymers of ethylene
oxide and propylene oxide (Pluronic) [51]. Interestingly,
these polymers can also be used for the retargeting of ade-
novirus [52].
Alternatively, the encapsulation of cationic complexes
in standard liposomes can be used to reduce nonspeciﬁc
interactions [53].
In addition to polymers, the coating of complexes
with protein could be used to mask positive charges, al-
though the protein itself may also introduce a bias of
biodistribution. Transferrin(Tf),apopularligandfortar-
geting to the transferrin receptor, also can be used to cre-
ate negatively charged complexes [54] or to mask the pos-
itive charge of PEI Tf polyplexes [55].
To achieve high-level transgene expression after suc-
cessful minimisation of the nonspeciﬁc interactions, it is
necessary to introduce an extrinsic functionality that me-
diates eﬃcient targeting and cellular uptake and replaces
the nonspeciﬁc binding and uptake.
EXTRINSIC TARGETING
In general, extrinsic targeting functions can be most
eﬃciently utilised when DNA-complexes are suﬃciently
inert, that is, their intrinsic, nonspeciﬁc interactions do
not unfavorably bias the biodistribution and interfere
with the targeting.
Such vectors can in fact be considered “detargeted,” as
the lack of nonspeciﬁc interactions leads to a reduced cel-
lular uptake and thus frequently makes these complexes
less eﬃcient in vitro than standard complexes. However,
once such complexes have been complemented by an ex-
trinsic targeting function they are well suited for speciﬁc,
high-resolution targeting in vivo. For the majority of ap-
plications, the extrinsic targeting functionality is based
onligand-receptorinteractionsbutotherapproachessuch
as, for example, the direction of paramagnetic complexes
through the use of an external magnetic ﬁeld are also be-
ing explored [56].
The binding of a “ligand” to a “receptor” (in the
broadest sense) provides the basis for most speciﬁc bio-
logical interactions and provides the blueprint for ligand-
based targeting strategies.
It is from this group of preexisting,“natural” ligands
or receptor substrates, many of the candidates used to tar-
get synthetic gene delivery systems have initially been se-
lected.
Preexistingligands
Endogenous
The most widely used preexisting targeting ligands
are based on endogenous molecules, which are already
presentinthebody. Preexisting ligandsareoftenrelatively
easily available and the receptor and its distribution are
fairly well studied.
Their use for targeting is based on the fact that a dif-
ferential of expression levels exists between the target site,
for example, tumour, and healthy tissue. A potential dis-
advantage of these ligands is the background expression
of the receptor in healthy tissues and the interference of
circulating endogenous ligand molecules.
The use of the vitamin folic acid as a ligand is an ex-
amples of the eﬀe c t i v eu s eo ft h en a t u r a lr e c e p t o rs u b -
strate for targeting. The development of targeted syn-
thetic vectors based on folate is a natural extension of the
use of this ligand for the targeting of drugs and imaging
agents [57]. The receptor for the vitamin, folic acid, is
overexpressed on a number of human tumors, including
cancers of the ovary, kidney, uterus, testis, brain, colon,154 Andreas G. Sch¨ atzlein 2003:2 (2003)
lung, and myelocytic blood cells [57]. In gene delivery,
folic acid has been used for the targeting of liposome-
encapsulated complexes [53], polylysine polyplexes [58],
andpolyethylenimine[59]polyplexestoreceptor-positive
cells.
Ar e c e n tr e p o r t[ 60] illustrates the eﬀect of intrinsic
bias on the targeting of folate lipoplexes in vivo: the lung
accumulation of the cationic complexes was successfully
reduced using masking with PEG polymer but targeting
of these complexes with folate failed to increase the accu-
mulation of the complexes in receptor-positive tumours,
probably because other intrinsic factors were overriding
the speciﬁc eﬀects. However, the folate ligand did have a
positive eﬀect on transfection eﬃciency in cells that had
taken up the complex.
For targeting of poly-L-lysine DNA-complexes to the
liver, asialoorosomucoid [61, 62]a n dgalactose [63, 64]
have been used as ligands. While uptake in hepatocytes
has been demonstrated for such systems, some of the liver
targeting may be caused by the tendency of the liver, and
speciﬁcally cells of the reticuloendothelial system (Kupfer
cells), to “ﬁlter” out particulate drug carriers.
Since its early use for the targeting to erythrob-
lasts [65] transferrin has become one of the most widely
used ligands for targeting of synthetic vectors. Trans-
ferrin receptors are found on the surface of most pro-
liferating cells and, in elevated numbers, on erythrob-
lasts and on many tumours [66, 67]. Its presence on
various cell types potentially limits the speciﬁcity of
transferrin-targeted vectors. There have been suggestions
that the eﬀects of transferrin on gene delivery may be
nonspeciﬁc and not related to targeting [68]. It has been
used in conjunction with lipoplexes [69], polyplexes pre-
pared from polylysine [70], PEI [71], or chitosan [48],
and with DNA-gelatin nanoparticles and DNA-binding
peptides [72].
Another important potential ligand for tumour tar-
geting is the epidermal growth factor (EGF) [73], which
has been used to target polylysine complexes [74], lipo-
somes [75] ,P E Ip o l y p l e x e s[ 74], and adenovirus-derived
peptides [76] to receptor-positive cells. There is currently
only limited experience with the use of EGF-targeted vec-
tors for targeting of synthetic vectors in vivo [77].
Exogenous
Manypathogenicorganismshavecoevolvedwiththeir
hosts and developed sophisticated targeting capabilities
that allow them to home on speciﬁc tissues and infect a
particular cell type [78]. If this targeting functionality can
be isolated from the organism’s pathogenicity, such lig-
ands would potentially be useful for targeting.
The malaria circumsporozoite (CS) protein, which
coats the entire surface of sporozoites of malaria parasites
and has been shown to bind speciﬁcally to the basolateral
surfaceof hepatocytes afterintravenous injection and also
to target polylysine polyplexes to these cells [79]. The pa-
pilloma virus capsid [80] is an example of a virus-derived
targeting ligand optimised by coevolution.
Denovoidentiﬁedligands
The development of targeted gene delivery vectors
tends to mirror the progress in drug delivery but with
a focus on the adaptation of techniques to the speciﬁc
challenges of synthetic gene delivery vectors. A number of
technologies for the de novo selection of potential bind-
ingligandssuchas,forexample,antibodies,phagedisplay,
combinatorial peptide, or nucleotide (aptamer) libraries,
have recently become widely available and recombinant
technology has greatly accelerated the discovery process.
(Currently, phage display [81] drives the move to smaller
targeting moieties such as antibody fragments [82, 83]
and peptides [84, 85].) Ligands derived from these tech-
nologies have a number of advantages, in particular with
respect to pharmaceutical, regulatory, and production is-
sues, and some have already been tested in the clinic.
Antibodies to the transferrin receptor [82], the anti-
platelet endothelial cell adhesion molecule PECAM [86],
the polymeric immunoglobulin receptor pIgR [83], anti-
CD5 [87], and the ErbB-2 receptor [88] have been used
for the targeting of liposomes [11, 89], polylysine poly-
plexes [90], PEI polyplexes [86], and DNA-peptide com-
plexes [91]. These systems in general mediated an in-
creased uptake or expression in vivo compared to the un-
targeted vector.
SUMMARY AND CONCLUSIONS
Safe,eﬃcient,andspeciﬁcdeliveryremainsapotential
bottleneck for the further development of gene therapy.
Each of the current systems has advantages and disadvan-
tagesandtheselectionofasuitablevectorneedstobeseen
in context with the therapeutic strategy.
Targeting strategies aim to increase the speciﬁcity of
a gene delivery formulation primarily through a modu-
lation of the carriers’ biodistribution, so that a dose dif-
ferential is created between healthy tissue and the target
site. In its simplest form, this can often be achieved by lo-
coregional administration of the formulation, for exam-
ple, intratumoural injection or inhalation for treatment
of the lung. Systemic, intravenous administration of gene
delivery system potentially allows targeting to (multiple)
remote sites. To allow speciﬁc distribution to the target
site, a carrier/complex should ideally be inert, that is, free
of intrinsic properties that would bias its biodistribution.
SyntheticvectorsystemspackagethetherapeuticDNA
in order to protect it from degradation, deliver it to the
target cells, and ﬁnally shuttle it to the nucleus to allow
expression of the transgene. Current systems protect the
DNA through the formation of electrostatic complexes
between cationic carrier and anionic DNA. The com-
plexes are particulate systems and tend to be positively
charged. Intrinsic physicochemical characteristics of the
complexsuchassizeandchargecanstronglyinﬂuencethe
biological properties.2003:2 (2003) Targeting of Synthetic Gene Delivery Systems 155
The bias of biodistribution introduced by the intrin-
sic physicochemical properties of synthetic delivery sys-
tems frequently interferes with other more speciﬁc means
oftargetingsuchasligands.However,whenusedinacon-
trolled manner, these intrinsic properties can also provide
a means of targeting in their own right, for example, the
accumulation of particulate and macromolecular systems
in tumours due to the enhanced penetration and reten-
tion eﬀect.
Strategies such as coating of complexes with hy-
drophilic polymers have been used successfully to camou-
ﬂage some of the interfering intrinsic properties of syn-
thetic vectors. As nonspeciﬁc interactions form an impor-
tant part of the cellular binding and uptake mechanism,
the masked charge needs to be replaced in order to main-
tain eﬃcient uptake and retain eﬃcacy.
Speciﬁc targeting is most frequently achieved by using
preexisting endogenous ligand-receptor interactions such
as folate-folate receptor and transferrin-transferrin recep-
tor. A potential drawback of endogenous ligand-receptor
interactions for targeting is the background from solu-
ble receptors, receptors in nontarget tissue, and the pres-
ence of circulating ligand. Antibodies are exogenous lig-
ands, which avoid some of these problems. Furthermore,
recent technologies for the identiﬁcation of ligands (eg,
phage display) have given access to a whole range of novel
ligands such as antibodies, antibody fragments, and pep-
tides.
A number of studies have recently demonstrated tar-
geting of synthetic delivery systems (eg, using folate [60])
to remote sites such as a tumour in animal models. More
importantly, tumour-targeted synthetic vectors in combi-
nation with a properly selected therapeutic gene can pro-
duce therapeutic eﬀects [92].
The diﬃculty of separating intrinsic and extrinsic tar-
geting eﬀectsrepresentsa signiﬁcant challengeforthe fur-
ther development of this ﬁeld. The inﬂuence of intrinsic
eﬀects and nonspeciﬁc interactions becomes more diﬃ-
cult to predict in the complex in vivo environment. Con-
sequently,thecorrelationbetweeninvitroandinvivoeﬃ-
cacyofadeliverysystemisnotoriouslyfragile.Thismeans
that well-controlled in vitro experiments are only of lim-
ited utility. The systematic optimisation of potentially
important targeting parameters such as aﬃnity/avidity,
chemistry of conjugation, and steric situation of the cou-
pling in vivo, however, is extremely challenging.
It is important to pursue the rapid technology trans-
fer into the clinic with intelligent combinations of syn-
thetic vector and therapeutic gene in order to validate the
use of such carriers in vivo, create clinical safety proﬁles,
and provide ﬁrst indications how animal models corre-
late with clinical experience. Bearing in mind the limita-
tions of current systems, it is however equally important
to gain a deeper understanding of the complex correla-
tion of physicochemistry and biology in order to be able
to rationally design vectors that overcome systemic, cellu-
lar, and molecular barriers to genetic therapy.
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